Cargando…

Immunogenicity of Current and New Therapies for Hemophilia A

Anti-drug antibody (ADA) development is a significant complication in the treatment of several conditions. For decades, the mainstay of hemophilia A treatment was the replacement of deficient coagulation factor VIII (FVIII) to restore hemostasis, control, and prevent bleeding events. Recently, new p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prezotti, Alessandra N. L., Frade-Guanaes, Jéssica O., Yamaguti-Hayakawa, Gabriela G., Ozelo, Margareth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331070/ https://www.ncbi.nlm.nih.gov/pubmed/35893734 http://dx.doi.org/10.3390/ph15080911

Ejemplares similares

Impact of novel hemophilia therapies around the world
por: Ozelo, Margareth C., et al.
Publicado: (2022)

Impaired repair properties of endothelial colony‐forming cells in patients with granulomatosis with polyangiitis
por: Del Rio, Ana Paula Toledo, et al.
Publicado: (2022)

Intermittent low platelet counts hampering diagnosis of X-linked thrombocytopenia in children: report of two unrelated cases and a novel mutation in the gene coding for the Wiskott-Aldrich syndrome protein
por: Medina, Samuel Souza, et al.
Publicado: (2017)

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
por: Shapiro, Amy D., et al.
Publicado: (2023)

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
por: Monahan, Paul E., et al.
Publicado: (2021)

Clotting Dysfunction in Sepsis: A Role for ROS and Potential for Therapeutic Intervention
por: Lopes-Pires, Maria Elisa, et al.
Publicado: (2021)

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2018)

Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
por: Chelle, Pierre, et al.
Publicado: (2019)

Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
por: Chelle, Pierre, et al.
Publicado: (2019)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Sports and Children with Hemophilia: Current Trends
por: Moretti, Lorenzo, et al.
Publicado: (2021)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

Current animal models of hemophilia: the state of the art
por: Yen, Ching-Tzu, et al.
Publicado: (2016)

Gene Therapy Approaches for the Treatment of Hemophilia B
por: Soroka, Anastasiia B., et al.
Publicado: (2023)

Emerging and future therapies for hemophilia
por: Carr, Marcus E, et al.
Publicado: (2015)

Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice
por: Lundgren, Taran S., et al.
Publicado: (2022)

Gene Therapy in Hemophilia: Recent Advances
por: Rodríguez-Merchán, E. Carlos, et al.
Publicado: (2021)

Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
por: Butros, Linda, et al.
Publicado: (2011)

Treatment of hemophilia: a review of current advances and ongoing issues
por: Coppola, Antonio, et al.
Publicado: (2010)

Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia
por: Badescu, Minerva Codruta, et al.
Publicado: (2022)

RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection
por: Boyce, Sara, et al.
Publicado: (2023)

Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A
por: Long, Brian R., et al.
Publicado: (2021)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Advanced therapies for the treatment of hemophilia: future perspectives
por: Liras, Antonio, et al.
Publicado: (2012)

Emerging therapies for hemophilia: controversies and unanswered questions
por: Arruda, Valder R., et al.
Publicado: (2018)

The Arrival of Gene Therapy for Patients with Hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2022)

Etranacogene dezaparvovec for hemophilia B gene therapy
por: Thornburg, Courtney D.
Publicado: (2021)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

Hemophilia therapy: the future has begun
por: Mannucci, Pier Mannuccio
Publicado: (2020)

Nonfactor Therapies for Hemophilia
por: Young, Guy
Publicado: (2023)

Current Therapeutic Approach to Acute Myocardial Infarction in Patients with Congenital Hemophilia
por: Badescu, Minerva Codruta, et al.
Publicado: (2021)

Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice
por: Pishko, Allyson M, et al.
Publicado: (2022)

The intersection of vector biology, gene therapy, and hemophilia
por: Lisowski, Leszek, et al.
Publicado: (2021)

Immunogenicity of biologic therapies for migraine: a review of current evidence
por: Cohen, Joshua M., et al.
Publicado: (2021)

New developments in the management of moderate-to-severe hemophilia B
por: Nazeef, Moniba, et al.
Publicado: (2016)

Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death
por: Asadzadeh, Zahra, et al.
Publicado: (2020)

Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries
por: Usuba, Koyo, et al.
Publicado: (2019)

Adenoviral Vectors for Hemophilia Gene Therapy
por: Brunetti-Pierri, N, et al.
Publicado: (2013)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?
por: Krumb, Evelien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dmoi1sq7a9098mhf92j1dv5p7s